GSK

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

GSK bags breakthrough status for bone cancer drug

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

News

Survival data graph from the DREAMM-7 trial

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

News

GSK builds neuro, cancer pipeline with trio of deals

GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

News

GSK drug raises hopes for patients with PBC itch

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC).

11 blockbuster drugs to look out for in 2025

GSK bags breakthrough status for bone cancer drug

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK builds neuro, cancer pipeline with trio of deals

A next-generation mindset: Veeva Commercial Summit 2024

GSK drug raises hopes for patients with PBC itch

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks